Werewolf Therapeutics, Inc. Common Stock (HOWL)

PHARMACEUTICAL PREPARATIONS

Headquarters
United States
Employees
14
Market Cap
$24M

About Werewolf Therapeutics, Inc. Common Stock

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.

SentiSense also tracks daily options readings for Werewolf Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.

Werewolf Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.